Menu
Recruiting NCT04358146

Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)

No phase Interventional Gastroesophageal Reflux in Children

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Experimental Infant formula, Infant formula thickened with locust bean gum.
Who it may be relevant to
Registry conditions: Gastroesophageal Reflux in Children. Basic parameters: 2 Weeks — 4 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium, France, Greece, Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial

Overview

The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.

Detailed description

The study duration is 1 month and 2 days. It is possible to add 2 additional months (optional).

The 2 first days (from D-3 to D0) correspond to the pre-selection period. These 2 days are followed by the follow-up month (from D0 to D30). It is possible to add an optional follow up of 2 months (form D30 to D90).

Interventions

  • Other Experimental Infant formula
    Exclusive formula feeding with the new infant formula thickened with fibers
  • Other Infant formula thickened with locust bean gum
    Exclusive formula feeding with the formula thickened with locust bean

Primary outcome measures

  • Frequency of regurgitation [Time frame: Day 14]
Secondary outcome measures (12)
  • Frequency of regurgitations [Time frame: Day 30, Day 90]
  • Severity of regurgitation episodes [Time frame: Day 14, Day 30, Day 90]
  • Stools' frequency [Time frame: Day 14, Day 30, Day 90]
  • Stools' consistency [Time frame: Day 14, Day 30, Day 90]
  • Frequency of diarrhea [Time frame: Day 14, Day 30, Day 90]
  • Severity of diarrhea [Time frame: Day 14, Day 30, Day 90]
  • Frequency of constipation [Time frame: Day 14, Day 30, Day 90]
  • Severity of constipation [Time frame: Day 14, Day 30, Day 90]
  • Crying time [Time frame: Day 14, Day 30, Day 90]
  • Feeding refusal [Time frame: Day 14, Day 30, Day 90]
  • Abnormal posturing [Time frame: Day 14, Day 30, Day 90]
  • Sleep quality [Time frame: Day 14, Day 30, Day 90]

Eligibility criteria

Inclusion criteria

  • ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days,
  • exclusive or predominant formula feeding
  • whose parents signed informed consent

Exclusion criteria

  • preterm infants or birthweight <2500g
  • Post enteritis lactose intolerance
  • Suspected or diagnosed cow's milk protein allergy requiring an eviction diet
  • Use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). All these medications have to be stopped at least 7 days before inclusion visit (V1)
  • Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

France · 6 centers
  • Center_09 — Castelnau-le-Lez
  • Center_02 — Étampes
  • Center_05 — Libourne
  • Centre_10 — Maromme
  • Center_16 — Nice
  • Center_08 — Vincennes
Belgium · 2 centers
  • Center_14 — Namur
  • Center_15 — Thuin
Greece · 2 centers
  • Center_01 — Athens
  • Center_11 — Thessaloniki
Italy · 2 centers
  • Center_12 — Naples
  • Center_13 — Naples

Identifiers

NCT: NCT04358146 · UP2017-04-STELLAR

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗